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Parabens are esters of p-hydroxybenzoic acid,
widely used as antimicrobial preservatives—
especially against molds and yeast—in cosmetic
products and pharmaceuticals and in food and
beverage processing (Elder 1984; Orth 1980;
Weber 1993). Cosmetics manufacturers and
food processers use methyl and propyl parabens
most extensively (Elder 1984; Jackson 1992).
Parabens are popular because of their low toxic-
ity and cost, broad inertness, and worldwide
regulatory acceptance (Soni et al. 2005).
Parabens are not mutagenic (Elder 1984), but
their potential estrogenic activity—although
many orders of magnitude lower than that of
estrogen (Golden et al. 2005; Routledge et al.
1998)— has raised some concerns about their
toxicity. In vitro data suggest that parabens
demonstrate weakly estrogen activities in yeast-
based assays (Miller et al. 2001; Nishihara et al.
2000; Routledge et al. 1998; Vinggaard et al.
2000), induce the growth of MCF-7 human
breast cancer cells, and inﬂuence the expression
of estrogen-dependent genes (Byford et al.
2002; Darbre et al. 2002, 2003; Okubo et al.
2001). On the other hand, increased uterine
weights have been reported in immature mice
after exposure to n-butyl, iso-butyl, and benzyl
parabens (Darbre et al. 2002). Decreased excre-
tion of testosterone and alterations in the male
reproductive tract were observed in male
rodents after exposure to butyl and propyl
parabens (Oishi 2001, 2002a, 2002b) but not
to methyl and ethyl parabens (Oishi 2004).
Ethyl, propyl, and butyl parabens evoked estro-
genic responses in sexually immature rainbow
trout, although the estrogenic potency of ethyl
paraben was weaker than that of propyl and
butyl paraben (Pedersen et al. 2000). 
Data on human exposure to parabens are
limited (Darbre et al. 2004; Makino 2003;
National Toxicology Program 2004), and the
toxic effects of parabens in humans are mostly
unknown. The detection (but not concentra-
tion ranges) of methyl paraben in cord blood
and breast milk has been reported (Makino
2003). A study on the presence of parabens in
human breast tumors (Darbre et al. 2004) trig-
gered debate over the use of parabens in cos-
metics, particularly in underarm deodorants
and antiperspirants, which may increase the
incidence of breast cancer (Darbre 2001,
2004, 2006; Elder 1984; Golden et al. 2005;
Harvey 2003, 2004; Harvey and Darbre 2004;
Harvey and Everett 2004). 
Such findings, involving as they do the
estrogenicity of parabens in animals and the
presence of parabens in human breast tissue,
have raised questions about the safety of wide-
spread paraben use, and these questions
prompted the Cosmetic Ingredient Review pro-
gram (established in 1976 by the Cosmetics,
Toiletry, and Fragrance Association), with the
support of the Food and Drug Administration
(FDA) and the Consumer Federation of
America, to reevaluate paraben safety (Bergfeld
et al. 2005). Furthermore, the National
Institute of Environmental Health Sciences
nominated butyl paraben for toxicological char-
acterization, including reproductive toxicity
studies (National Toxicology Program 2004). 
After intraduodenal or intravenous
administration (2 mg/kg) in rats, parabens are
mainly hydrolyzed to p-hydroxybenzoic acid,
which can then be conjugated with glycine,
glucuronide, and sulfate and excreted in urine
(Cashman and Warshaw 2005; Kiwada et al.
1979, 1980; Soni et al. 2005). In rabbits, after
oral administration of methyl-, ethyl-, propyl-,
and butyl parabens at doses of 0.4 and
0.8 g/kg, a small percentage (0.2–0.9%) of the
unchanged paraben was excreted in the urine
(Tsukamoto and Terade 1960, 1962, 1964). 
Although human toxicokinetic data are
limited, some reports state that after oral
administration of propyl paraben (2 g for
5 days) to a human volunteer, only 17.4% of
the administered dose was recovered as
p-hydroxybenzoic acid and its conjugates in
urine (Sabalitschka 1954). Another report con-
cerning six preterm infants who were injected
intramuscularly with a paraben-containing
gentamicin formulation showed that the uri-
nary excretion of methyl paraben could range
from 13.2 to 88.1% (Hindmarsh et al. 1983).
Most of the methyl paraben was excreted in
urine in its conjugated form. 
Measuring p-hydroxybenzoic acid or its
conjugates in urine may not represent the
optimal approach for assessing human expo-
sure to parabens. p-Hydroxybenzoic acid is a
nonspecific metabolite of all parabens, and
individual parabens are known to have quite
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BACKGROUND: Parabens appear frequently as antimicrobial preservatives in cosmetic products, in
pharmaceuticals, and in food and beverage processing. In vivo and in vitro studies have revealed
weak estrogenic activity of some parabens. Widespread use has raised concerns about the potential
human health risks associated with paraben exposure. 
OBJECTIVES: Assessing human exposure to parabens usually involves measuring in urine the conju-
gated or free species of parabens or their metabolites. In animals, parabens are mostly hydrolyzed to
p-hydroxybenzoic acid and excreted in the urine as conjugates. Still, monitoring urinary concentra-
tions of p-hydroxybenzoic acid is not necessarily the best way to assess exposure to parabens.
p-Hydroxybenzoic acid is a nonspecific biomarker, and the varying estrogenic bioactivities of
parabens require speciﬁc biomarkers. Therefore, we evaluated the use of free and conjugated parent
parabens as new biomarkers for human exposure to these compounds.
RESULTS: We measured the urinary concentrations of methyl, ethyl, n-propyl, butyl (n- and iso-),
and benzyl parabens in a demographically diverse group of 100 anonymous adults. We detected
methyl and n-propyl parabens at the highest median concentrations (43.9 ng/mL and 9.05 ng/mL,
respectively) in nearly all (> 96%) of the samples. We also detected other parabens in more than
half of the samples (ethyl, 58%; butyl, 69%). Most important, however, we found that parabens in
urine appear predominantly in their conjugated forms. 
CONCLUSIONS: The results, demonstrating the presence of urinary conjugates of parabens in
humans, suggest that such conjugated parabens could be used as exposure biomarkers. Additionally,
the fact that conjugates appear to be the main urinary products of parabens may be important for
risk assessment. 
KEYWORDS: biomonitoring, conjugate, ethylparaben, metabolism, methylparaben, butylparaben,
n-propylparaben, p-hydroxybenzoic acid esters, urine. Environ Health Perspect 114:1843–1846
(2006). doi:10.1289/ehp.9413 available via http://dx.doi.org/ [Online 29 August 2006]different estrogenic bioactivities (Golden et al.
2005). In the present study, we evaluated the
use of the free and conjugated species of the
parent parabens as new biomarkers for human
exposure to these compounds.
Materials and Methods
Methyl, ethyl, n-propyl, n-butyl, and benzyl
paraben, 4-methylumbelliferyl glucuronide,
4-methylumbelliferyl sulfate, and β-glucuro-
nidase/sulfatase (Helix pomatia, H1) were
purchased from Sigma Chemical Co. (St.
Louis, MO). 13C4-4-Methylumbelliferone
was purchased from Cambridge Isotope
Laboratories, Inc. (Andover, MA). d4-Methyl
paraben was purchased from C/D/N Isotopes
Inc. (Quebec, Canada). d4-Ethyl, d4-n-propyl,
and d4-n-butyl parabens were obtained from
CanSyn Chem Corp. (Toronto, Canada).
Because d4-benzyl parabens was not available,
d4-n-butyl paraben was used as the internal
standard for benzyl paraben. The urine sam-
ples analyzed for this study were collected
anonymously from a demographically diverse
group of 100 U.S. male and female adults
with no known exposure to parabens. The
samples were collected from 2003 to 2005 at
different times throughout the day—not nec-
essarily first morning voids. The Centers for
Disease Control and Prevention Human
Subjects Institutional Review Board reviewed
and approved the study protocol. A waiver of
informed consent was requested under the
Code of Federal Regulations dealing with
human subjects [45 CFR 46.116(d)].
We measured the total concentrations of
methyl, ethyl, n-propyl, butyl (n- and iso-), and
benzyl parabens with a modification of a
method for measuring other environmental
phenols in urine (Ye et al. 2005a) using online
solid-phase extraction high-performance liquid
chromatography–tandem mass spectrometry
(SPE-HPLC-MS/MS) (Ye et al. 2006). Brieﬂy,
100 μL urine was spiked with 50 μL internal
standard solution, 50 μL enzyme solution,
and, to monitor the completion of the decon-
jugation reaction, 10 μL 4-methylumbelliferyl
glucuronide/4-methylumbelliferyl sulfate/13C4-
4-methylumbelliferone standard solution (Ye
et al. 2006). Samples were incubated for 4 hr
at 37°C and then acidiﬁed with 0.1 M formic
acid. The online SPE-HPLC-MS/MS system
consisted of several Agilent 1100 modules
(Agilent Technologies, Wilmington, DE)—
two binary HPLC pumps, an autosampler
with a 900-μL injection loop, and one column
compartment with a 10-port switching valve,
and an API 4000 triple quadrupole mass spec-
trometer (Applied Biosystems, Foster City,
CA) equipped with an atmospheric pressure
chemical ionization interface. The procedure
for extracting the deconjugated parabens from
the urine involved concurrent online SPE-
HPLC operation with peak focusing. While
the autosampler and one of the HPLC pumps
were used for the SPE cleanup of one sample,
the 10-port switching valve, the second HPLC
pump, and the mass spectrometer were used to
collect data from the previous sample (Ye et al.
2006). The limits of detection (LODs), calcu-
lated as 3S0, where S0 is the standard deviation
as the concentration approaches zero (Taylor
1987), were 0.13 ng/mL (methyl paraben),
0.18 ng/mL (n-propyl paraben), and 0.1
ng/mL (ethyl, butyl, and benzyl parabens) (Ye
et al. 2006).
To determine the concentrations of the
free species (Cfree), we followed the above pro-
cedure without the enzymatic hydrolysis treat-
ment. We used β-glucuronidase (Escherichia
coli-K12; Roche Applied Science, Penzberg,
Germany) to selectively deconjugate glu-
curonide metabolites and determine the con-
centrations of free plus glucuronidated species
(Cfree+glu). Similarly, we used β-glucuronidase/
sulfatase (H. pomatia, 463 000U/g solid) to
deconjugate both glucuronide and sulfate
metabolites and to determine the concentra-
tions of free plus glucuronidated plus sulfated
species (Cfree+glu+sul). We calculated the con-
centration of glucuronide conjugates by sub-
tracting Cfree from Cglu+free. Similarly, we
calculated the concentration of sulfate
metabolites by subtracting Cfree+glu+sul from
Cfree+glu (Ye et al. 2005b).
To ensure accuracy and precision of the
data, we analyzed quality control (QC) materi-
als along with the samples. Low-concentration
(QCL, 2–5 ng/mL) and high-concentration
(QCH, 10–50 ng/mL) QC materials were pre-
pared from a base urine pool obtained from
multiple anonymous donors (Ye et al. 2006).
The materials were dispensed in 1-mL aliquots
and stored at –70°C. Each QC material was
characterized to deﬁne the mean and the 95%
and 99% control limits of parabens concentra-
tions using a minimum of 40 repeated meas-
urements during a 2-week period. 
We performed the statistical analyses
using the Statistical Analysis System (SAS
Institute, Cary, NC) software. For concentra-
tions below the LOD, we used a value equal
to the LOD divided by the square root of 2
(Hornung and Reed 1990). Statistical signiﬁ-
cance was set at p < 0.05. 
Results and Discussion
We measured total (i.e., free plus glu-
curonidated and sulfated conjugates) concen-
trations of ﬁve parabens in 100 human urine
samples collected between 2003 and 2005
from 100 adult anonymous volunteers with no
known occupational exposure to these com-
pounds. The median concentrations, selected
Ye et al.
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Table 1. Total (free plus conjugated) and free urinary concentrations of parabens (ng/mL) at selected per-
centiles, and frequency of detection in adults (n = 100).
Frequency of  Percentile
Compound detection (%) 5th 25th 50th 75th 90th 95th
Methyl paraben, total 99 4.2 14.6 43.9 180 412 680
Methyl paraben, free 75 < LOD 0.1 0.8 4.7 15.0 27.8
Ethyl paraben, total 58 < LOD < LOD 1.0 6.9 25.1 47.5
Ethyl paraben, free 22 < LOD < LOD < LOD < LOD 0.5 1.5
n-Propyl paraben, total 96 0.2 1.9 9.1 49.2 144 279
n-Propyl paraben, free 37 < LOD < LOD < LOD 0.4 1.8 3.4
Butyl paraben, total 69 < LOD < LOD 0.5 3.3 14.5 29.5
Butyl paraben, free 17 < LOD < LOD < LOD < LOD 0.2 0.3
Benzyl paraben, total 39 < LOD < LOD < LOD 0.2 0.4 0.5
Benzyl paraben, free 0 < LOD < LOD < LOD < LOD < LOD < LOD
The LODs were 0.13 ng/mL (methyl paraben), 0.18 ng/mL (n-propyl paraben), and 0.10 ng/mL (ethyl, butyl, and benzyl
parabens). For the statistical calculations, concentrations < LOD were imputed a value of LOD divided by the square root of 2. 
Figure 1. Correlation analyses of total urinary con-
centrations of methyl and n-propyl parabens limited
to samples with detectable levels of each paraben
(n = 93; r = 0.92; p < 0.0001). Conc, concentration.
When all samples were included in the analysis, the
r- and p-values were very similar.
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Figure 2. Correlation analyses of total versus free
concentrations of methyl paraben for samples with
detectable values (n = 83; r = 0.67; p < 0.0001). Conc,
concentration. When all samples (n = 100) were
included in the analysis, we obtained very similar
r- and p-values. 
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10percentiles, and frequency of detection of each
paraben are all shown in Table 1. 
Methyl and n-propyl paraben were detected
in almost all of the samples (99% and 96%,
respectively). Two other parabens were detected
in more than half of the samples (ethyl, 58%;
butyl, 69%); benzyl paraben was detected less
frequently (39%) (Table 1). Median urinary
concentrations were highest for methyl (43.9
ng/mL) and n-propyl (9.1 ng/mL) parabens.
Methyl paraben was also the most abundant
(mean value of 12.8 ng/g) among 6 parabens
tested in human breast tumors (Darbre et al.
2004). The higher frequency of detection and
median urinary concentrations of methyl and
n-propyl parabens could be related to a) the fact
that these are the most widely used parabens in
cosmetics and food processing (Jackson 1992),
b) differences in the absorption, distribution,
metabolism, and excretion of the various
parabens, or c) a combination of these factors.
Furthermore, the high correlation (Pearson cor-
relation coefficient r = 0.92, p < 0.0001)
between total urinary concentrations of methyl
and n-propyl parabens (Figure 1) suggests that
human exposures to methyl and n-propyl
parabens most likely share common sources.
Differences in metabolic proﬁles have been
found depending on the exposure route (Bando
et al. 1997; Daston 2005; Harvey 2005; Soni
et al. 2005). After oral administration, parabens
are most likely hydrolyzed by nonspecific
esterases, widely distributed in the body,
including the gut (Daston 2005). After dermal
exposure, parabens can also be hydrolyzed by
esterases present in human skin and subcuta-
neous fat tissue (Lobemeier et al. 1996). The
presence of unchanged parabens in breast
tumor tissues (Darbre et al. 2004) suggested,
however, that at least a fraction of the parabens
can be absorbed without hydrolysis. The high
frequency of detection of some parabens in our
study confirms that, after exposure, unhy-
drolyzed parabens may be excreted in urine.
The median concentrations of free methyl,
ethyl, and n-propyl parabens were lower than
their corresponding median total concentra-
tions (Table 1). For methyl and n-propyl
parabens, the total concentrations were about
50- and 10-fold higher, respectively, than the
median concentrations of free species. This
suggests that these parabens are mostly
excreted in urine as conjugates (Table 1).
Moreover, the correlations between the con-
centrations of free and total (free plus conju-
gated) species of methyl and n-propyl
parabens were highly signiﬁcant (p < 0.0001
and p = 0.0096, respectively; Figure 2). In
other words, high concentrations of total
methyl- or n-propyl parabens tended to be
related to high concentrations of the corre-
sponding free paraben. These ﬁndings suggest
that parabens, like many xenobiotics, undergo
phase II biotransformations to produce
glucuronide or sulfate conjugates with increased
water solubility that are more amenable to uri-
nary excretion than are the free species
(de Wildt et al. 1999; Wang and James 2006).
If the biologically active compound were the
free species (van den Berg et al. 2003), urinary
excretion of the conjugated species would
reduce the bioavailable concentration of the free
species for target organs, thus minimizing the
potential adverse effects related to parabens
exposure. 
We also examined the distribution of glu-
curonide and sulfate conjugates of parabens
(Table 2). The sulfate conjugate represented
67% (methyl paraben) and 55% (n-propyl
paraben) of the total amount of each paraben
excreted in urine. The percentage of the glu-
curonide conjugate was 28% for methyl
paraben, and 43% for n-propyl paraben; only
a small amount of these parabens was excreted
in free form (5% for methyl and 2% for
n-propyl). The urinary concentrations of both
glucuronide and sulfate conjugates correlated
well with the concentrations of the total species
(r ranged from 0.78 to 0.93) (Figure 3). The
concentration of conjugated species increased
with the concentration of total species, even at
the highest concentrations of total species.
These ﬁndings are in agreement with data on
exposure of humans to phthalates, another
class of environmental chemicals (Silva et al.
2006). The ﬁndings also suggest that satura-
tion or inhibition of the enzymes catalyzing the
glucuronidation or sulfatation reactions did
not occur at environmental exposure levels. 
In conclusion, our preliminary data sug-
gest that parabens can be present in urine,
mostly in their conjugated form. To our
knowledge, this is the first comprehensive
report on the urinary concentrations of indi-
vidual parabens and their conjugates in
humans. The high frequency of detection for
methyl, ethyl, n-propyl, and butyl parabens
suggests that parabens and their conjugates
could be valid biomarkers to assess human
exposures to these compounds. Additional
Parabens as biomarkers of exposure
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Table 2. Urinary concentrations of the free, glucuronidated, and sulfated conjugates of methyl and
n-propyl parabens in adults (n = 100).
Frequency of Median Range Percentage of
Compound detection (%) (ng/mL) (ng/mL) total amount
Methyl paraben, free 75 0.8 < LOD–717 5
Methyl paraben, glucuronide 85 9.7 < LOD–1,670 28
Methyl paraben, sulfate 96 29.9 < LOD–1,300 67
n-Propyl paraben, free 37 < LOD < LOD–95.0 2
n-Propyl paraben, glucuronide 64 3.2 < LOD–820 43
n-Propyl paraben, sulfate 83 5.2 < LOD–424 55
The LODs were 0.13 ng/mL (methyl paraben) and 0.18 ng/mL (n-propyl paraben). For the statistical calculations, concen-
trations < LOD were imputed a value of LOD divided by the square root of 2. 
Figure 3. Correlation analyses of total versus conjugated concentrations of (A) glucuronidated and (B) sul-
fated methyl paraben, and (C) glucuronidated and (D) sulfated n-propyl paraben. Concentrations < LOD
were excluded in the graphical representations (n varied from 65 to 97, r-values ranged from 0.78 to 0.93,
p < 0.0001). Conc, concentration. When all 100 samples were included in the analyses, the r- and p-values
were very similar. 
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to exposure and to internal dose. 
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